Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjögren's Syndrome: A Pilot Study
Open Access
- 1 November 2013
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 65 (11), 1862-1868
- https://doi.org/10.1002/acr.22052
Abstract
Objective To prospectively evaluate histopathologic, blood cellular, serologic, and clinical changes in response to abatacept treatment in patients with primary Sjögren's syndrome (SS). Methods Blood, saliva, and minor salivary gland biopsy samples were obtained before and after the last of 8 doses of abatacept in 11 primary SS patients. The histologic data evaluated the numbers of lymphocytic foci and B and T cell subtypes (CD20+, CD3+, CD4+, and CD8+). The numbers of FoxP3+ regulatory T cells were measured and the FoxP3:CD3 ratio was calculated. Histologic data were compared with results from peripheral blood and with changes in saliva secretion. Results The numbers of lymphocytic foci decreased significantly (P = 0.041). Numbers of local FoxP3+ T cells decreased significantly in percentage of total lymphocytic infiltrates (P = 0.037). In the peripheral blood, B cells increased (P = 0.038). This was due to an expansion of the naive B cell pool (P = 0.034). When adjusting for disease duration, an increase was also noted for total lymphocytes (P = 0.044) and for CD4 cells (P = 0.009). Gamma globulins decreased significantly (P = 0.005), but IgG reduction did not reach significance. Adjusted for disease duration, saliva production increased significantly (P = 0.029). Conclusion CTLA-4Ig treatment significantly reduces glandular inflammation in primary SS, induces several cellular changes, and increases saliva production. Remarkably, this increase in saliva production is significantly influenced by disease duration.Keywords
This publication has 19 references indexed in Scilit:
- Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndromeArthritis Research & Therapy, 2012
- The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndromeAutoimmunity Reviews, 2010
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- Characteristics of the minor salivary gland infiltrates in Sjögren's syndromeJournal of Autoimmunity, 2009
- Safety and usefulness of minor salivary gland biopsy: Retrospective analysis of 502 procedures performed at a single centerArthritis Care & Research, 2008
- Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot studyAnnals Of The Rheumatic Diseases, 2007
- Sjögren's syndromeThe Lancet, 2005
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjogren's syndrome.Annals Of The Rheumatic Diseases, 1987
- A quantitative test for xerostomia. The saxon test, an oral equivalent of the schirmer testArthritis & Rheumatism, 1985